Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 1/2021

Open Access 01-01-2021 | Chronic Inflammatory Bowel Disease | Review

The gut mycobiome: a novel player in chronic liver diseases

Authors: Lu Jiang, Peter Stärkel, Jian-Gao Fan, Derrick Eugene Fouts, Petra Bacher, Bernd Schnabl

Published in: Journal of Gastroenterology | Issue 1/2021

Login to get access

Abstract

The human gut microbiome (bacteria, fungi, viruses, and archaea) is a complex and diverse ecosystem. It plays an important role in human health, but is involved in several intestinal and extraintestinal diseases. Most research to date has focused on the role of bacteria, while studies focusing on fungi (also referred to as “mycobiome” or “fungome”) are still in its infancy. In this review, we focus on the existing literature available about the gut mycobiome with an emphasis on compositional mycobiome changes associated with liver diseases, the impact on pathogenesis of disease, and its potential use as therapeutic targets. We also provide insights into current methodologies of studying mycobiome, and we highlight the interkingdom interactions in the context of disease and how they affect health of the host. Herein, by focusing on the gut mycobiome, this review provides novel insights and directions for liver research.
Literature
1.
Clemente JC, Ursell LK, Parfrey LW, et al. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.PubMedPubMedCentral
2.
Huseyin CE, O’Toole PW, Cotter PD, et al. Forgotten fungi-the gut mycobiome in human health and disease. FEMS Microbiol Rev. 2017;41:479–511.PubMed
3.
Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313–23.PubMedPubMedCentral
4.
Lai GC, Tan TG, Pavelka N. The mammalian mycobiome: a complex system in a dynamic relationship with the host. Wiley Interdiscip Rev Syst Biol Med. 2019;11:e1438.PubMed
5.
Hernández-Santos N, Klein BS. Through the scope darkly: the gut mycobiome comes into focus. Cell Host Microbe. 2017;22:728–9.PubMedPubMedCentral
6.
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.PubMedPubMedCentral
7.
Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019;16:331–45.PubMed
8.
Seed PC. The human mycobiome. Cold Spring Harb Perspect Med. 2014;5:a019810.PubMed
9.
Redecker D, Kodner R, Graham LE. Glomalean fungi from the Ordovician. Science. 2000;289:1920–1.PubMed
10.
Blackwell M. The fungi: 1, 2, 3… 5.1 million species? Am J Bot. 2011;98:426–38.PubMed
11.
12.
Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome. 2017;5:153.PubMedPubMedCentral
13.
Dupuy AK, David MS, Li L, et al. Redefining the human oral mycobiome with improved practices in amplicon-based taxonomy: discovery of Malassezia as a prominent commensal. PLoS ONE. 2014;9:e90899.PubMedPubMedCentral
14.
Zhang E, Tanaka T, Tajima M, et al. Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol Immunol. 2011;55:625–32.PubMed
15.
Huseyin CE, Rubio RC, O’Sullivan O, et al. The fungal frontier: a comparative analysis of methods used in the study of the human gut mycobiome. Front Microbiol. 2017;8:1432.PubMedPubMedCentral
16.
Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. 2015;6:89.PubMedPubMedCentral
17.
Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010;6:e1000713.PubMedPubMedCentral
18.
Peters BA, Wu J, Hayes RB, et al. The oral fungal mycobiome: characteristics and relation to periodontitis in a pilot study. BMC Microbiol. 2017;17:157.PubMedPubMedCentral
19.
Burge HA. An update on pollen and fungal spore aerobiology. J Allergy Clin Immunol. 2002;110:544–52.PubMed
20.
Charlson ES, Diamond JM, Bittinger K, et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am J Respir Crit Care Med. 2012;186:536–45.PubMedPubMedCentral
21.
Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS ONE. 2013;8:e66019.PubMedPubMedCentral
22.
Gaitanis G, Magiatis P, Hantschke M, et al. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012;25:106–41.PubMedPubMedCentral
23.
Jo JH, Deming C, Kennedy EA, et al. Diverse human skin fungal communities in children converge in adulthood. J Invest Dermatol. 2016;136:2356–63.PubMedPubMedCentral
24.
Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15.PubMed
25.
Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):rv13.
26.
27.
Bacher P, Hohnstein T, Beerbaum E, et al. Human anti-fungal Th17 Immunity and pathology rely on cross-reactivity against candida albicans. Cell. 2019;176(1340–55):e15.
28.
Sparber F, De Gregorio C, Steckholzer S, et al. the skin commensal yeast malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe. 2019;25(389–403):e6.
29.
Jiang L, Schnabl B. Gut microbiota in liver disease: what do we know and what do we not know? Physiol (Bethesda). 2020;35:261–74.
30.
Thomas S, Izard J, Walsh E, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res. 2017;77:1783–812.PubMedPubMedCentral
31.
Foster KR, Schluter J, Coyte KZ, et al. The evolution of the host microbiome as an ecosystem on a leash. Nature. 2017;548:43–51.PubMedPubMedCentral
32.
Forbes JD, Bernstein CN, Tremlett H, et al. A fungal world: could the gut mycobiome be involved in neurological disease? Front Microbiol. 2018;9:3249.PubMed
33.
Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat Rev Immunol. 2017;17:635–46.PubMedPubMedCentral
34.
35.
Scheffold A, Bacher P. Anti-fungal T cell responses in the lung and modulation by the gut-lung axis. Curr Opin Microbiol. 2020;56:67–73.PubMed
36.
Vinh DC. Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis. 2011;11:780–92.PubMed
37.
Mengesha BG, Conti HR. The role of IL-17 in protection against mucosal candida infections. J Fungi (Basel). 2017;3(4):52.
38.
Li J, Casanova JL, Puel A. Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation. Mucosal Immunol. 2018;11:581–9.PubMed
39.
Corvilain E, Casanova JL, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38:656–93.PubMedPubMedCentral
40.
Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:367–80.PubMedPubMedCentral
41.
Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.PubMed
42.
Shao TY, Ang WXG, Jiang TT, et al. Commensal candida albicans positively calibrates systemic Th17 immunological responses. Cell Host Microbe. 2019;25(404–17):e6.
43.
Bacher P, Heinrich F, Stervbo U, et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell. 2016;167(1067–78):e16.
44.
Rizzetto L, Kuka M, De Filippo C, et al. Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J Immunol. 2010;184:4258–68.PubMed
45.
Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039–48.PubMed
46.
Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104:1745–53.PubMed
47.
Limon JJ, Tang J, Li D, et al. Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe. 2019;25(377–88):e6.
48.
Lang S, Duan Y, Liu J, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020;71:522–38.PubMed
49.
Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127:2829–41.PubMedPubMedCentral
50.
51.
Bajaj JS, Liu EJ, Kheradman R, et al. Fungal dysbiosis in cirrhosis. Gut. 2018;67:1146–54.PubMed
52.
Wheeler ML, Limon JJ, Bar AS, et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe. 2016;19:865–73.PubMedPubMedCentral
53.
Sovran B, Planchais J, Jegou S, et al. Enterobacteriaceae are essential for the modulation of colitis severity by fungi. Microbiome. 2018;6:152.PubMedPubMedCentral
54.
Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentral
55.
Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130:1764–75.PubMed
56.
Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196:97–105.PubMed
57.
Gomes AL, Teijeiro A, Buren S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30:161–75.PubMed
58.
Parfieniuk-Kowerda A, Swiderska M, Szulzyk T, et al. Serum concentrations of Th17-associated interleukins and autoimmune phenomena are associated with the degree of liver damage in alcoholic liver disease. J Gastrointestin Liver Dis. 2017;26:269–74.PubMed
59.
60.
Chiaro TR, Soto R, Zac Stephens W, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med. 2017;9(380):eaaf9044.PubMedPubMedCentral
61.
62.
Napolitano M, Patruno C. Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease. Med Hypotheses. 2018;116:96–100.PubMed
63.
64.
Scanlan PD, Marchesi JR. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J. 2008;2:1183–93.PubMed
65.
Hamad I, Sokhna C, Raoult D, et al. Molecular detection of eukaryotes in a single human stool sample from Senegal. PLoS ONE. 2012;7:e40888.PubMedPubMedCentral
66.
Gouba N, Raoult D, Drancourt M. Plant and fungal diversity in gut microbiota as revealed by molecular and culture investigations. PLoS ONE. 2013;8:e59474.PubMedPubMedCentral
67.
Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020;72:391–400.PubMed
68.
Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol. 1996;34:58–61.PubMedPubMedCentral
69.
Kaneko T, Makimura K, Onozaki M, et al. Vital growth factors of Malassezia species on modified CHROMagar Candida. Med Mycol. 2005;43:699–704.PubMed
70.
Hamad I, Ranque S, Azhar EI, et al. Culturomics and amplicon-based metagenomic approaches for the study of fungal population in human gut microbiota. Sci Rep. 2017;7:16788.PubMedPubMedCentral
71.
Anderson IC, Cairney JW. Diversity and ecology of soil fungal communities: increased understanding through the application of molecular techniques. Environ Microbiol. 2004;6:769–79.PubMed
72.
Iwen PC, Hinrichs SH, Rupp ME. Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens. Med Mycol. 2002;40:87–109.PubMed
73.
Schoch CL, Seifert KA, Huhndorf S, et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci USA. 2012;109:6241–6.PubMedPubMedCentral
74.
Tang J, Iliev ID, Brown J, et al. Mycobiome: approaches to analysis of intestinal fungi. J Immunol Methods. 2015;421:112–21.PubMedPubMedCentral
75.
Nilsson RH, Ryberg M, Kristiansson E, et al. Taxonomic reliability of DNA sequences in public sequence databases: a fungal perspective. PLoS ONE. 2006;1:e59.PubMedPubMedCentral
76.
Koljalg U, Larsson KH, Abarenkov K, et al. UNITE: a database providing web-based methods for the molecular identification of ectomycorrhizal fungi. New Phytol. 2005;166:1063–8.PubMed
77.
Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature. 2013;498:367–70.PubMedPubMedCentral
78.
Schoch CL, Robbertse B, Robert V, et al. Finding needles in haystacks: linking scientific names, reference specimens and molecular data for fungi. Database (Oxford). 2014;2014:bau061PubMedCentral
79.
Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012;56(Suppl 1):S39-45.PubMed
80.
Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology. 2020;71:306–33.PubMed
81.
Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–24.PubMed
82.
Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148:30–6.PubMed
83.
Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575:505–11.PubMedPubMedCentral
84.
Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS ONE. 2013;8:e53028.PubMedPubMedCentral
85.
86.
Maccioni L, Gao B, Leclercq S, et al. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes. 2020;12:1782157.PubMedPubMedCentral
87.
Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33.PubMed
88.
Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.PubMed
89.
90.
Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–25.PubMed
91.
Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.PubMed
92.
93.
You N, Zhuo L, Zhou J, et al. the role of intestinal fungi and its metabolites in chronic liver diseases. Gut Liver. 2020;14:291–6.PubMed
94.
Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5:111–25.PubMedPubMedCentral
95.
Everard A, Matamoros S, Geurts L, et al. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio. 2014;5:e11011–4.
96.
Liu YT, Li YQ. Wang YZ [Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2016;24:921–6.PubMed
97.
Lemoinne S, Kemgang A, Ben Belkacem K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69:92–102.PubMed
98.
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391:2547–59.PubMed
99.
Shah A, Macdonald GA, Morrison M, et al. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Off J Am Coll Gastroenterol. 2020;115(6):814–22.
100.
Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019;25:659–71.PubMedPubMedCentral
101.
Little R, Wine E, Kamath BM, et al. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol. 2020;26:2768–80.PubMedPubMedCentral
102.
Trivedi PJ, Tickle J, Vesterhus MN, et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67:1135–45.PubMed
103.
Ruhlemann M, Liwinski T, Heinsen FA, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019;50:580–9.PubMedPubMedCentral
104.
Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473–6.PubMedPubMedCentral
105.
Rudolph G, Gotthardt D, Kloters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149–55.PubMed
106.
Oztas E, Odemis B, Kekilli M, et al. Systemic phaeohyphomycosis resembling primary sclerosing cholangitis caused by Exophiala dermatitidis. J Med Microbiol. 2009;58:1243–6.PubMed
107.
Hong KH, Kim JW, Jang SJ, et al. Liver cirrhosis caused by Exophiala dermatitidis. J Med Microbiol. 2009;58:674–7.PubMed
108.
El Bialy SA, El Kader KF, El-Ashmawy MB. Current progress in antifibrotics. Curr Med Chem. 2011;18:3082–92.PubMed
109.
Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.PubMed
110.
Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72.PubMed
111.
Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64.PubMed
112.
Chen Y, Chen Z, Guo R, et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn Microbiol Infect Dis. 2011;70:492–8.PubMed
113.
Choo SP, Tan WL, Goh BKP, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430–46.PubMed
114.
Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014.PubMed
115.
Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69:107–20.PubMed
116.
Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013;22:305–10.PubMed
117.
Lopez C, Ramos L, Bulacio L, et al. Aflatoxin B1 content in patients with hepatic diseases. Med (B Aires). 2002;62:313–6.
118.
Hamid AS, Tesfamariam IG, Zhang Y, et al. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: geographical distribution, mechanism of action and prevention. Oncol Lett. 2013;5:1087–92.PubMedPubMedCentral
119.
Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–67.PubMed
120.
Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:405–9.PubMed
121.
122.
Garsin DA, Lorenz MC. Candida albicans and Enterococcus faecalis in the gut: synergy in commensalism? Gut Microbes. 2013;4:409–15.PubMedPubMedCentral
123.
Markey L, Shaban L, Green ER, et al. Pre-colonization with the commensal fungus Candida albicans reduces murine susceptibility to Clostridium difficile infection. Gut Microbes. 2018;9:497–509.PubMedPubMedCentral
Metadata
Title
The gut mycobiome: a novel player in chronic liver diseases
Authors
Lu Jiang
Peter Stärkel
Jian-Gao Fan
Derrick Eugene Fouts
Petra Bacher
Bernd Schnabl
Publication date
01-01-2021
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 1/2021
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01740-5

Other articles of this Issue 1/2021

Journal of Gastroenterology 1/2021 Go to the issue

Editorial

Diagnosis for Wilson disease: this disease may not be a rare disease

Original Article—Alimentary Tract

Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease

Original Article—Liver, Pancreas, and Biliary Tract

Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites

Original Article—Liver, Pancreas, and Biliary Tract

The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy

Original Article—Liver, Pancreas, and Biliary Tract

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

Original Article—Liver, Pancreas, and Biliary Tract

Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits